Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Sincerest congratulations to our clients who are being recognized among Stony Brook University’s 40 under 40 for 2016. Since earning their Stony Brook degree, they have gone on to pursue their passions, help others and lead positive change.
Joseph Scaduto ’08, MBA Business Administration – Founder and CEO, Traverse Biosciences Inc.
Additionally, warmest wishes of continued success to Stony Brook’s Director of Government Relations, Lauren Brookmeyer, who was recently named a Long Island Business News “40 under 40 Class of 2017” honoree.
Vitatex, a Stony Brook-based biotechnology company located in the Long Island High Technology Incubator, has announced that it was awarded an SBIR Phase I/II Fast Track contract in September 2015 from the National Cancer Institute (NCI) for its Vita-Cap™ CTC Capture and Preservation tubes. A modification to exercise the option for a two-year SBIR Phase II of the contract was executed on June 8, 2016.
Vitatex Inc. provides proprietary invasive circulating tumor cell (iCTC) enrichment technology and products to develop revolutionary cancer genetic and cell tests. These “liquid biopsies” focus on next generation sequencing (NGS) detection, gene expression profiling and flow cytometry and have recently been adopted by the clinical laboratory community to characterize cancer cells and/or their RNA/DNA in blood samples non-invasively and serially, and to acquire genetic alternations and drug resistance information, which have the potential to replace tests run on surgical biopsies.
Clinical metastasis of solid tumors is linked to blood-borne dissemination of viable tumor cells in the circulation and clinical instrumentation is now available to isolate, enumerate, culture, generate metastatic mouse models and perform molecular analyses on these circulating tumor cells (CTCs). However, CTCs are fragile and tend to degrade within a few days when collected in standard blood collection tubes.
“The functional CTC preparation tube is designed to collect, enrich and preserve the viability/functionality of cancer cells in blood all within a closed system” said Wen-Tien Chen, PhD., Chief Scientific Officer of Vitatex. “The goal is to define conditions of Vitatex CTC preparation tubes for capturing and preserving cancer cells in the blood of patients with breast, ovarian and other types for up to 96 hours of transit.”
Specific terms of the contract were not disclosed.
Codagenix, a CFB client company, has announced that it has been awarded a $99,710 Phase I Small Business Innovation Research (SBIR) grant from the United States Department of Agriculture (USDA) to commence the development of an influenza vaccine for swine. Codagenix will apply its next-generation platform technology to construct a vaccine against influenza viruses that infect swine, which, according to the USDA’s 2014 Census of Agriculture is a $22.5 billion industry here in the United States. Read more here.
Rosyln Heights, NY-based Ortek Therapeutics announced that the U.S. Patent and Trademark Office has awarded a patent for new methods to use new compositions to prevent or treat drug-resistant bacteria and suppress body odor.
U.S. Patent 9,370,476, was issued to The Research Foundation of State University of New York, an Ortek licensing partner, and is directed to topical application of a zinc and arginine-based composition. Ortek holds exclusive international licensing rights to this patent, which was developed at Stony Brook University. Ortek has a long-standing relationship with Israel Kleinberg DDS, PhD, DSc, who led the development of this new technology and is the Director of the Division of Translational Oral Biology at Stony Brook University.
Traverse Biosciences has announced a collaboration with SUNY Updated Medical University on a $164,689 Peer Reviewed Medical Research Program (PRMRP) Discovery Award from the U.S. Department of Defense. The research will be led by Gary Nieman, Associate Professor and Senior Research Scientist in the Department of Surgery and will evaluate the effectiveness of the company’s lead drug candidate, TRB-N0224, to treat acute lung injury, including acute respiratory distress syndrome (ARDS). Read more here.